Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 11 |
| List of Tables | 10 | 2 |
| List of Figures | 12 | 1 |
| Introduction | 13 | 1 |
| Global Markets Direct Report Coverage | 13 | 1 |
| Osteoarthritis Pain Overview | 14 | 1 |
| Therapeutics Development | 15 | 2 |
| Pipeline Products for Osteoarthritis Pain Overview | 15 | 1 |
| Pipeline Products for Osteoarthritis Pain Comparative Analysis | 16 | 1 |
| Osteoarthritis Pain Therapeutics under Development by Companies | 17 | 3 |
| Osteoarthritis Pain Therapeutics under Investigation by Universities/Institutes | 20 | 1 |
| Osteoarthritis Pain Pipeline Products Glance | 21 | 4 |
| Late Stage Products | 21 | 1 |
| Clinical Stage Products | 22 | 1 |
| Early Stage Products | 23 | 1 |
| Unknown Stage Products | 24 | 1 |
| Osteoarthritis Pain Products under Development by Companies | 25 | 4 |
| Osteoarthritis Pain Products under Investigation by Universities/Institutes | 29 | 1 |
| Osteoarthritis Pain Companies Involved in Therapeutics Development | 30 | 39 |
| AbbVie Inc | 30 | 1 |
| Addex Therapeutics Ltd | 31 | 1 |
| Afferent Pharmaceuticals, Inc. | 32 | 1 |
| Akron Molecules AG | 33 | 1 |
| Allergan Plc | 34 | 1 |
| Ampio Pharmaceuticals, Inc. | 35 | 1 |
| Antibe Therapeutics, Inc. | 36 | 1 |
| Aralez Pharmaceuticals Inc. | 37 | 1 |
| Arena Pharmaceuticals, Inc. | 38 | 1 |
| Array BioPharma Inc. | 39 | 1 |
| AskAt Inc. | 40 | 1 |
| Astellas Pharma Inc. | 41 | 1 |
| Axsome Therapeutics Inc | 42 | 1 |
| Biogen Inc | 43 | 1 |
| Boehringer Ingelheim GmbH | 44 | 1 |
| Cara Therapeutics, Inc. | 45 | 1 |
| Centrexion Therapeutics Corp | 46 | 1 |
| Chromocell Corporation | 47 | 1 |
| Eli Lilly and Company | 48 | 1 |
| Elite Pharmaceuticals, Inc. | 49 | 1 |
| Eupraxia Pharmaceuticals Inc. | 50 | 1 |
| Flexion Therapeutics, Inc. | 51 | 1 |
| Genzyme Corporation | 52 | 1 |
| GlaxoSmithKline Plc | 53 | 1 |
| Glenmark Pharmaceuticals Ltd. | 54 | 1 |
| Grunenthal GmbH | 55 | 1 |
| Iroko Pharmaceuticals, LLC | 56 | 1 |
| Medestea Research &Production S.p.A. | 57 | 1 |
| MedImmune, LLC | 58 | 1 |
| Nuvo Pharmaceuticals Inc. | 59 | 1 |
| Pfizer Inc. | 60 | 1 |
| Phosphagenics Limited | 61 | 1 |
| pSivida Corp. | 62 | 1 |
| Purdue Pharma LP | 63 | 1 |
| Regeneron Pharmaceuticals Inc | 64 | 1 |
| Symic Biomedical, Inc. | 65 | 1 |
| Taiwan Liposome Company, Ltd. | 66 | 1 |
| Vertex Pharmaceuticals Incorporated | 67 | 1 |
| Zynerba Pharmaceuticals Inc | 68 | 1 |
| Osteoarthritis Pain Therapeutics Assessment | 69 | 15 |
| Assessment by Monotherapy Products | 69 | 1 |
| Assessment by Combination Products | 70 | 1 |
| Assessment by Target | 71 | 4 |
| Assessment by Mechanism of Action | 75 | 5 |
| Assessment by Route of Administration | 80 | 2 |
| Assessment by Molecule Type | 82 | 2 |
| Drug Profiles | 84 | 110 |
| (amlodipine besylate + celecoxib) Drug Profile | 84 | 3 |
| (lidocaine + tetracaine) Drug Profile | 87 | 2 |
| (naltrexone hydrochloride + oxycodone hydrochloride) SR Drug Profile | 89 | 1 |
| 2-CCPA Drug Profile | 90 | 1 |
| AAT-008 Drug Profile | 91 | 1 |
| adefovir dipivoxil Drug Profile | 92 | 1 |
| ADX-71441 Drug Profile | 93 | 3 |
| AF-219 Drug Profile | 96 | 4 |
| Ampion Drug Profile | 100 | 8 |
| Antisense Oligonucleotide to Block SCN9A for Erythromelalgia, Neuropathic Pain, Osteoarthritis Pain and Rheumatoid Arthritis Pain Drug Profile | 108 | 1 |
| APD-371 Drug Profile | 109 | 1 |
| AQU-010 Drug Profile | 110 | 1 |
| ARRY-954 Drug Profile | 111 | 1 |
| AS-288640100 Drug Profile | 112 | 1 |
| ASP-7962 Drug Profile | 113 | 1 |
| ATB-346 Drug Profile | 114 | 4 |
| AXIBU-01 Drug Profile | 118 | 1 |
| BI-1026706 Drug Profile | 119 | 1 |
| capsaicin Drug Profile | 120 | 2 |
| CC-8464 Drug Profile | 122 | 2 |
| cebranopadol Drug Profile | 124 | 3 |
| celecoxib Drug Profile | 127 | 1 |
| CR-4056 Drug Profile | 128 | 1 |
| CRB-0089 Drug Profile | 129 | 1 |
| dapansutrile Drug Profile | 130 | 1 |
| difelikefalin Drug Profile | 131 | 8 |
| duloxetine hydrochloride DR Drug Profile | 139 | 2 |
| ELS-130 Drug Profile | 141 | 1 |
| fasinumab Drug Profile | 142 | 3 |
| fluticasone propionate ER Drug Profile | 145 | 1 |
| GRC-27864 Drug Profile | 146 | 1 |
| GSK-3196165 Drug Profile | 147 | 3 |
| GZ-389988 Drug Profile | 150 | 1 |
| ibuprofen Drug Profile | 151 | 1 |
| MED-1101 Drug Profile | 152 | 1 |
| MEDI-7352 Drug Profile | 153 | 1 |
| naproxen sodium Drug Profile | 154 | 1 |
| NEO-5937 Drug Profile | 155 | 1 |
| NEO-6860 Drug Profile | 156 | 1 |
| onabotulinumtoxin A Drug Profile | 157 | 5 |
| oxycodone ER Drug Profile | 162 | 3 |
| PA-300 DR Drug Profile | 165 | 1 |
| PA-65020 Drug Profile | 166 | 1 |
| SB-061 Drug Profile | 167 | 1 |
| Small Molecule for Osteoarthritis Pain Drug Profile | 168 | 1 |
| Small Molecule to Antagonize P2Y14 for Osteoarthritic Pain Drug Profile | 169 | 1 |
| Small Molecules for Osteoarthritis Pain Drug Profile | 170 | 1 |
| Small Molecules to Block Calcium Ion Channel for Osteoarthritis Pain Drug Profile | 171 | 1 |
| Small Molecules to Block Nav1.7 for Osteoarthritis Pain Drug Profile | 172 | 1 |
| Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain Drug Profile | 173 | 1 |
| Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation Drug Profile | 174 | 1 |
| Small Molecules to Inhibit PDE2 for Osteoarthritis Pain Drug Profile | 175 | 1 |
| tanezumab Drug Profile | 176 | 3 |
| TLC-599 Drug Profile | 179 | 2 |
| triamcinolone acetonide sodium phosphate SR Drug Profile | 181 | 5 |
| VG-201 Drug Profile | 186 | 1 |
| VM-902A Drug Profile | 187 | 1 |
| VX-150 Drug Profile | 188 | 1 |
| zoledronic acid Drug Profile | 189 | 2 |
| ZYN-002 Drug Profile | 191 | 3 |
| Osteoarthritis Pain Dormant Projects | 194 | 5 |
| Osteoarthritis Pain Discontinued Products | 199 | 2 |
| Osteoarthritis Pain Product Development Milestones | 201 | 10 |
| Featured News &Press Releases | 201 | 1 |
| Oct 17, 2016: Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs | 201 | 1 |
| Sep 27, 2016: Kitov Reports Successful Results for Additional KIT-302 Pharmacokinetic Bioequivalence Study | 202 | 1 |
| Sep 15, 2016: Cara Therapeutics Initiates Enrollment in Phase 2b Trial of Peripherally Acting Kappa Opioid Agonist, Oral CR845, in Chronic Pain Patients | 202 | 1 |
| Sep 14, 2016: Flexion Therapeutics Announces Appointment of Mark Stejbach to its Board of Directors | 203 | 1 |
| Sep 12, 2016: Flexion Therapeutics Announces Two Key Corporate Appointments | 203 | 1 |
| Sep 06, 2016: Kitov Pharmaceuticals to Present Data From a U.S. Market Assessment for KIT-302 | 204 | 1 |
| Aug 10, 2016: Kitov Announces Issuance of U.S. Patent Securing Long-Term Exclusivity for KIT-302 Ahead of New Drug Application to the FDA | 205 | 1 |
| Aug 03, 2016: Ampio Updates Regulatory Status of AMPION | 205 | 1 |
| Jul 06, 2016: Flexion Therapeutics Adds Three New Executives in Key Roles to Support the Planned Commercial Launch of Zilretta | 206 | 1 |
| Jun 30, 2016: Ampio announces results of Ampion trials | 207 | 1 |
| Jun 28, 2016: Kitov Lead Drug KIT-302 Achieves Manufacturing Milestone Ahead of Planned NDA Filing with U.S. FDA | 207 | 1 |
| Jun 24, 2016: Kitov Reports New Data Demonstrating KIT-302 Has Beneficial Effects on Kidney Function | 208 | 1 |
| May 30, 2016: Antibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide Conference | 209 | 1 |
| May 27, 2016: Kitov Announces Completion of Manufacturing Pivotal Batches of KIT-302 Required for Registration in the U.S. | 209 | 1 |
| May 26, 2016: Flexion Therapeutics Receives Positive Guidance from FDA on New Drug Application (NDA) Submission for Zilretta for Osteoarthritis of the Knee | 210 | 1 |
| Appendix | 211 | 2 |
| Methodology | 211 | 1 |
| Coverage | 211 | 1 |
| Secondary Research | 211 | 1 |
| Primary Research | 211 | 1 |
| Expert Panel Validation | 211 | 1 |
| Contact Us | 211 | 1 |
| Disclaimer | 212 | 1 |